- Home
- Publications
- Publication Search
- Publication Details
Title
Daratumumab for the Treatment of Multiple Myeloma
Authors
Keywords
-
Journal
Frontiers in Immunology
Volume 9, Issue -, Pages -
Publisher
Frontiers Media SA
Online
2018-06-04
DOI
10.3389/fimmu.2018.01228
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- CD38-NAD + Axis Regulates Immunotherapeutic Anti-Tumor T Cell Response
- (2018) Shilpak Chatterjee et al. Cell Metabolism
- Ninety-minute daratumumab infusion is safe in multiple myeloma
- (2018) Hallie Barr et al. LEUKEMIA
- Daratumumab plus Bortezomib, Melphalan, and Prednisone for Untreated Myeloma
- (2018) María-Victoria Mateos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Expression of CD38 in myeloma bone niche: A rational basis for the use of anti-CD38 immunotherapy to inhibit osteoclast formation
- (2017) Federica Costa et al. Oncotarget
- Roles and Modalities of Ectonucleotidases in Remodeling the Multiple Myeloma Niche
- (2017) Antonella Chillemi et al. Frontiers in Immunology
- Phase 1/2 study of daratumumab, lenalidomide, and dexamethasone for relapsed multiple myeloma
- (2016) T. Plesner et al. BLOOD
- Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma
- (2016) Saad Z. Usmani et al. BLOOD
- CD38 expression and complement inhibitors affect response and resistance to daratumumab therapy in myeloma
- (2016) Inger S. Nijhof et al. BLOOD
- Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma
- (2016) J. Krejcik et al. BLOOD
- Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference
- (2016) Christopher McCudden et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA)
- (2016) Niels W.C.J. van de Donk et al. CLINICAL CHEMISTRY AND LABORATORY MEDICINE
- Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial
- (2016) Sagar Lonial et al. LANCET
- Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma
- (2016) Meletios A. Dimopoulos et al. NEW ENGLAND JOURNAL OF MEDICINE
- Daratumumab, Bortezomib, and Dexamethasone for Multiple Myeloma
- (2016) Antonio Palumbo et al. NEW ENGLAND JOURNAL OF MEDICINE
- Dealing with anti-CD38 (daratumumab) interference in blood compatibility testing
- (2016) Karen M.K. De Vooght et al. TRANSFUSION
- International validation of a dithiothreitol (DTT)-based method to resolve the daratumumab interference with blood compatibility testing
- (2016) Claudia I. Chapuy et al. TRANSFUSION
- Clinical efficacy and management of monoclonal antibodies targeting CD38 and SLAMF7 in multiple myeloma
- (2015) N. W. C. J. van de Donk et al. BLOOD
- Immunophenotype of normal vs. myeloma plasma cells: Toward antibody panel specifications for MRD detection in multiple myeloma
- (2015) Juan Flores-Montero et al. CYTOMETRY PART B-CLINICAL CYTOMETRY
- Upregulation of CD38 expression on multiple myeloma cells by all-trans retinoic acid improves the efficacy of daratumumab
- (2015) I S Nijhof et al. LEUKEMIA
- Targeting CD38 with Daratumumab Monotherapy in Multiple Myeloma
- (2015) Henk M. Lokhorst et al. NEW ENGLAND JOURNAL OF MEDICINE
- When blood transfusion medicine becomes complicated due to interference by monoclonal antibody therapy
- (2015) Marlies Oostendorp et al. TRANSFUSION
- Resolving the daratumumab interference with blood compatibility testing
- (2015) Claudia I. Chapuy et al. TRANSFUSION
- NAD+-Metabolizing Ectoenzymes in Remodeling Tumor–Host Interactions: The Human Myeloma Model
- (2015) Alberto Horenstein et al. Cells
- Robust isolation of malignant plasma cells in multiple myeloma
- (2014) I. Frigyesi et al. BLOOD
- The therapeutic human CD38 antibody daratumumab improves the anti-myeloma effect of newly emerging multi-drug therapies
- (2011) M S van der Veer et al. Blood Cancer Journal
- Towards effective immunotherapy of myeloma: enhanced elimination of myeloma cells by combination of lenalidomide with the human CD38 monoclonal antibody daratumumab
- (2010) M. S. van der Veer et al. HAEMATOLOGICA
- Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors
- (2010) M. de Weers et al. JOURNAL OF IMMUNOLOGY
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExploreDiscover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversation